MHRA comparator product guidance
Comparator products in bioequivalence/therapeutic equivalence studies
Current edition
Last updated 20 December 2024
Current edition
Last updated 20 December 2024
About this standard
Explains when a comparator product sourced outside the UK can be used in bioequivalence and therapeutic equivalence studies for abridged applications, and what bridging data are needed.
Recognition by market
Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts
No market listing is published yet.
Testing requirements that cite it
Open the market page and its pathway pages for the full requirement, protocol and report content
United Kingdom
- Comparator products from outside the UK in bioequivalence studiesBioequivalence · Not stated
Related standards: JP guideline for bioequivalence studies of generic products, CPMP/EWP/QWP/1401/98 Rev 1, JP BE guideline, formulation changes (oral solid), NMPA Notice 2016 No. 61, Annex 3, FDA BE guidance for ANDAs (PK endpoints), NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9, M13A. See all standards.